

Rimiducid

Catalog No: tcsc3162



Available Sizes

Size: 2mg

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

195514-63-7

Formula:

$C_{78}H_{98}N_4O_{20}$

Pathway:

Apoptosis

Target:

TNF Receptor

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 54 mg/mL (38.25 mM)

Alternative Names:

AP1903

Observed Molecular Weight:

1411.63

Product Description


Rimiducid (AP1903) is a dimerizer agent that acts by cross-linking the **FKBP** domains, initiating **Fas** signaling and hence **apoptosis**.

IC50 & Target: EC50: 0.1 nM (FKBP, in HT1080 cells)^[1]

Fas receptor^[1]

In Vitro: The human fibrosarcoma line HT1080 is engineered to express stably a fusion protein comprising a myristoylation sequence, two copies of F36V-FKBP, and the human first apoptosis signal (Fas) intracellular domain. Rimiducid (AP1903) elicits potent and dose-dependent apoptotic death of these engineered cells in culture, with an EC₅₀ of ≈ 0.1 nM^[1]. Maximal killing occurred in the presence of 3 to 10 nM Rimiducid (AP1903), and the IC₅₀ is approximately 0.2 nM. LVVFas-transduced T lymphocytes expressing high levels of CD25 (top panel) are eliminated by with $66\% \pm 7.5\%$ (n=10) efficiency. When cells are examined after CD25 expression returned to basal levels, $63\% \pm 4.7\%$ (n=9) killing is observed after Rimiducid treatment^[2].

In Vivo: Rimiducid (AP1903; i.v., 0.01, 0.1, 1, 10, and 100 mg/kg) elicits a dose-dependent decrease in serum hGH levels, with a half-maximal effective dose of 0.4 ± 0.1 mg/kg^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!